Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
ECMOHeparinRespiratory Failure
Interventions
DRUG

subcutaneous heparin anticoagulation

The primary objective of this study is to evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure. Subjects will be prospectively randomized in 1:1 ratio to subcutaneous heparin anticoagulation or systemic intravenous anticoagulation and followed until 1 week after discontinuation from ECMO support.

Trial Locations (1)

75246

RECRUITING

Baylor Scott & White Health research institute, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER